Selected research
Industry Research
Integrin Inhibitors Industry Research Report 2026
Market perspective
The global Integrin Inhibitors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Integrin Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Integrin Inhibitors is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Integrin Inhibitors is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Integrin Inhibitors include Grand Pharmaceutical, Yangtze River Pharmaceutical, Tianjin Chase Sun Pharma, SJZ No.4 Pharmaceutical, Lunan Pharma, Kelun Pharma, Huadong Medicin, Bio-Thera Solutions and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Integrin Inhibitors market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Integrin Inhibitors Market by Company
Grand Pharmaceutical
Yangtze River Pharmaceutical
Tianjin Chase Sun Pharma
SJZ No.4 Pharmaceutical
Lunan Pharma
Kelun Pharma
Huadong Medicin
Bio-Thera Solutions
Takeda
Taj Pharmaceuticals
Sandoz
Polpharma Biologics
Novartis
Merck
Medicure
Johnson & Johnson
GlaxoSmithKline
Gland Pharma
Eli Lilly
Correvio
Biogen
Alvotech
Integrin Inhibitors Segment by Type
Antibodies
Small Molecules
Others
Integrin Inhibitors Segment by Application
Cardiovascular Disease
Tumor
Autoimmune Disease
Other
Integrin Inhibitors Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Integrin Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Integrin Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Integrin Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Integrin Inhibitors manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Integrin Inhibitors by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Integrin Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Integrin Inhibitors Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Integrin Inhibitors Sales (K Units) of Manufacturers (2021-2026)
Table 7. Global Integrin Inhibitors Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Integrin Inhibitors Revenue of Manufacturers (2021-2026)
Table 9. Global Integrin Inhibitors Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Integrin Inhibitors Average Price (US$/Unit) of Manufacturers (2021-2026)
Table 11. Global Integrin Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Integrin Inhibitors, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Integrin Inhibitors, Product Type & Application
Table 14. Global Integrin Inhibitors Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Integrin Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Grand Pharmaceutical Company Information
Table 19. Grand Pharmaceutical Business Overview
Table 20. Grand Pharmaceutical Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 21. Grand Pharmaceutical Integrin Inhibitors Product Portfolio
Table 22. Grand Pharmaceutical Recent Developments
Table 23. Yangtze River Pharmaceutical Company Information
Table 24. Yangtze River Pharmaceutical Business Overview
Table 25. Yangtze River Pharmaceutical Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 26. Yangtze River Pharmaceutical Integrin Inhibitors Product Portfolio
Table 27. Yangtze River Pharmaceutical Recent Developments
Table 28. Tianjin Chase Sun Pharma Company Information
Table 29. Tianjin Chase Sun Pharma Business Overview
Table 30. Tianjin Chase Sun Pharma Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 31. Tianjin Chase Sun Pharma Integrin Inhibitors Product Portfolio
Table 32. Tianjin Chase Sun Pharma Recent Developments
Table 33. SJZ No.4 Pharmaceutical Company Information
Table 34. SJZ No.4 Pharmaceutical Business Overview
Table 35. SJZ No.4 Pharmaceutical Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 36. SJZ No.4 Pharmaceutical Integrin Inhibitors Product Portfolio
Table 37. SJZ No.4 Pharmaceutical Recent Developments
Table 38. Lunan Pharma Company Information
Table 39. Lunan Pharma Business Overview
Table 40. Lunan Pharma Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 41. Lunan Pharma Integrin Inhibitors Product Portfolio
Table 42. Lunan Pharma Recent Developments
Table 43. Kelun Pharma Company Information
Table 44. Kelun Pharma Business Overview
Table 45. Kelun Pharma Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 46. Kelun Pharma Integrin Inhibitors Product Portfolio
Table 47. Kelun Pharma Recent Developments
Table 48. Huadong Medicin Company Information
Table 49. Huadong Medicin Business Overview
Table 50. Huadong Medicin Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 51. Huadong Medicin Integrin Inhibitors Product Portfolio
Table 52. Huadong Medicin Recent Developments
Table 53. Bio-Thera Solutions Company Information
Table 54. Bio-Thera Solutions Business Overview
Table 55. Bio-Thera Solutions Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 56. Bio-Thera Solutions Integrin Inhibitors Product Portfolio
Table 57. Bio-Thera Solutions Recent Developments
Table 58. Takeda Company Information
Table 59. Takeda Business Overview
Table 60. Takeda Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 61. Takeda Integrin Inhibitors Product Portfolio
Table 62. Takeda Recent Developments
Table 63. Taj Pharmaceuticals Company Information
Table 64. Taj Pharmaceuticals Business Overview
Table 65. Taj Pharmaceuticals Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 66. Taj Pharmaceuticals Integrin Inhibitors Product Portfolio
Table 67. Taj Pharmaceuticals Recent Developments
Table 68. Sandoz Company Information
Table 69. Sandoz Business Overview
Table 70. Sandoz Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Sandoz Integrin Inhibitors Product Portfolio
Table 72. Sandoz Recent Developments
Table 73. Polpharma Biologics Company Information
Table 74. Polpharma Biologics Business Overview
Table 75. Polpharma Biologics Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Polpharma Biologics Integrin Inhibitors Product Portfolio
Table 77. Polpharma Biologics Recent Developments
Table 78. Novartis Company Information
Table 79. Novartis Business Overview
Table 80. Novartis Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Novartis Integrin Inhibitors Product Portfolio
Table 82. Novartis Recent Developments
Table 83. Merck Company Information
Table 84. Merck Business Overview
Table 85. Merck Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Merck Integrin Inhibitors Product Portfolio
Table 87. Merck Recent Developments
Table 88. Medicure Company Information
Table 89. Medicure Business Overview
Table 90. Medicure Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Medicure Integrin Inhibitors Product Portfolio
Table 92. Medicure Recent Developments
Table 93. Johnson & Johnson Company Information
Table 94. Johnson & Johnson Business Overview
Table 95. Johnson & Johnson Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Johnson & Johnson Integrin Inhibitors Product Portfolio
Table 97. Johnson & Johnson Recent Developments
Table 98. GlaxoSmithKline Company Information
Table 99. GlaxoSmithKline Business Overview
Table 100. GlaxoSmithKline Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. GlaxoSmithKline Integrin Inhibitors Product Portfolio
Table 102. GlaxoSmithKline Recent Developments
Table 103. Gland Pharma Company Information
Table 104. Gland Pharma Business Overview
Table 105. Gland Pharma Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Gland Pharma Integrin Inhibitors Product Portfolio
Table 107. Gland Pharma Recent Developments
Table 108. Eli Lilly Company Information
Table 109. Eli Lilly Business Overview
Table 110. Eli Lilly Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Eli Lilly Integrin Inhibitors Product Portfolio
Table 112. Eli Lilly Recent Developments
Table 113. Correvio Company Information
Table 114. Correvio Business Overview
Table 115. Correvio Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Correvio Integrin Inhibitors Product Portfolio
Table 117. Correvio Recent Developments
Table 118. Biogen Company Information
Table 119. Biogen Business Overview
Table 120. Biogen Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Biogen Integrin Inhibitors Product Portfolio
Table 122. Biogen Recent Developments
Table 123. Alvotech Company Information
Table 124. Alvotech Business Overview
Table 125. Alvotech Integrin Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Alvotech Integrin Inhibitors Product Portfolio
Table 127. Alvotech Recent Developments
Table 128. Global Integrin Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 129. Global Integrin Inhibitors Sales by Region (2021-2026) & (K Units)
Table 130. Global Integrin Inhibitors Sales Market Share by Region (2021-2026)
Table 131. Global Integrin Inhibitors Sales by Region (2027-2032) & (K Units)
Table 132. Global Integrin Inhibitors Sales Market Share by Region (2027-2032)
Table 133. Global Integrin Inhibitors Revenue by Region (2021-2026) & (US$ Million)
Table 134. Global Integrin Inhibitors Revenue Market Share by Region (2021-2026)
Table 135. Global Integrin Inhibitors Revenue by Region (2027-2032) & (US$ Million)
Table 136. Global Integrin Inhibitors Revenue Market Share by Region (2027-2032)
Table 137. North America Integrin Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 138. North America Integrin Inhibitors Sales by Country (2021-2026) & (K Units)
Table 139. North America Integrin Inhibitors Sales by Country (2027-2032) & (K Units)
Table 140. North America Integrin Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 141. North America Integrin Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 142. Europe Integrin Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 143. Europe Integrin Inhibitors Sales by Country (2021-2026) & (K Units)
Table 144. Europe Integrin Inhibitors Sales by Country (2027-2032) & (K Units)
Table 145. Europe Integrin Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 146. Europe Integrin Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 147. Asia Pacific Integrin Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 148. Asia Pacific Integrin Inhibitors Sales by Country (2021-2026) & (K Units)
Table 149. Asia Pacific Integrin Inhibitors Sales by Country (2027-2032) & (K Units)
Table 150. Asia Pacific Integrin Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 151. Asia Pacific Integrin Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 152. South America Integrin Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 153. South America Integrin Inhibitors Sales by Country (2021-2026) & (K Units)
Table 154. South America Integrin Inhibitors Sales by Country (2027-2032) & (K Units)
Table 155. South America Integrin Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 156. South America Integrin Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 157. Middle East and Africa Integrin Inhibitors Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 158. Middle East and Africa Integrin Inhibitors Sales by Country (2021-2026) & (K Units)
Table 159. Middle East and Africa Integrin Inhibitors Sales by Country (2027-2032) & (K Units)
Table 160. Middle East and Africa Integrin Inhibitors Revenue by Country (2021-2026) & (US$ Million)
Table 161. Middle East and Africa Integrin Inhibitors Revenue by Country (2027-2032) & (US$ Million)
Table 162. Global Integrin Inhibitors Sales by Type (2021-2026) & (K Units)
Table 163. Global Integrin Inhibitors Sales by Type (2027-2032) & (K Units)
Table 164. Global Integrin Inhibitors Sales Market Share by Type (2021-2026)
Table 165. Global Integrin Inhibitors Sales Market Share by Type (2027-2032)
Table 166. Global Integrin Inhibitors Revenue by Type (2021-2026) & (US$ Million)
Table 167. Global Integrin Inhibitors Revenue by Type (2027-2032) & (US$ Million)
Table 168. Global Integrin Inhibitors Revenue Market Share by Type (2021-2026)
Table 169. Global Integrin Inhibitors Revenue Market Share by Type (2027-2032)
Table 170. Global Integrin Inhibitors Price by Type (2021-2026) & (US$/Unit)
Table 171. Global Integrin Inhibitors Price by Type (2027-2032) & (US$/Unit)
Table 172. Global Integrin Inhibitors Sales by Application (2021-2026) & (K Units)
Table 173. Global Integrin Inhibitors Sales by Application (2027-2032) & (K Units)
Table 174. Global Integrin Inhibitors Sales Market Share by Application (2021-2026)
Table 175. Global Integrin Inhibitors Sales Market Share by Application (2027-2032)
Table 176. Global Integrin Inhibitors Revenue by Application (2021-2026) & (US$ Million)
Table 177. Global Integrin Inhibitors Revenue by Application (2027-2032) & (US$ Million)
Table 178. Global Integrin Inhibitors Revenue Market Share by Application (2021-2026)
Table 179. Global Integrin Inhibitors Revenue Market Share by Application (2027-2032)
Table 180. Global Integrin Inhibitors Price by Application (2021-2026) & (US$/Unit)
Table 181. Global Integrin Inhibitors Price by Application (2027-2032) & (US$/Unit)
Table 182. Key Raw Materials
Table 183. Raw Materials Key Suppliers
Table 184. Integrin Inhibitors Distributors List
Table 185. Integrin Inhibitors Customers List
Table 186. Integrin Inhibitors Industry Trends
Table 187. Integrin Inhibitors Industry Drivers
Table 188. Integrin Inhibitors Industry Restraints
Table 189. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Integrin Inhibitors Product Image
Figure 5. Global Integrin Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Integrin Inhibitors Market Size (2021-2032) & (US$ Million)
Figure 7. Global Integrin Inhibitors Sales (2021-2032) & (K Units)
Figure 8. Global Integrin Inhibitors Average Price (US$/Unit) & (2021-2032)
Figure 9. Antibodies Product Image
Figure 10. Small Molecules Product Image
Figure 11. Others Product Image
Figure 12. Cardiovascular Disease Product Image
Figure 13. Tumor Product Image
Figure 14. Autoimmune Disease Product Image
Figure 15. Other Product Image
Figure 16. Global Integrin Inhibitors Revenue Share by Manufacturers in 2025
Figure 17. Global Manufacturers of Integrin Inhibitors, Manufacturing Sites & Headquarters
Figure 18. Global Top 5 and 10 Integrin Inhibitors Players Market Share by Revenue in 2025
Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 20. Global Integrin Inhibitors Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 21. Global Integrin Inhibitors Sales by Region in 2025
Figure 22. Global Integrin Inhibitors Revenue by Region in 2025
Figure 23. North America Integrin Inhibitors Market Size by Country in 2025
Figure 24. North America Integrin Inhibitors Sales Market Share by Country (2021-2032)
Figure 25. North America Integrin Inhibitors Revenue Market Share by Country (2021-2032)
Figure 26. United States Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 27. Canada Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 28. Mexico Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 29. Europe Integrin Inhibitors Market Size by Country in 2025
Figure 30. Europe Integrin Inhibitors Sales Market Share by Country (2021-2032)
Figure 31. Europe Integrin Inhibitors Revenue Market Share by Country (2021-2032)
Figure 32. Germany Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 33. France Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. U.K. Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. Italy Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. Russia Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 37. Spain Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Netherlands Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. Switzerland Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. Sweden Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Poland Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. Asia Pacific Integrin Inhibitors Market Size by Country in 2025
Figure 43. Asia Pacific Integrin Inhibitors Sales Market Share by Country (2021-2032)
Figure 44. Asia Pacific Integrin Inhibitors Revenue Market Share by Country (2021-2032)
Figure 45. China Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 46. Japan Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. South Korea Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 48. India Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. Australia Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. Taiwan Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Southeast Asia Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. Southeast Asia Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 53. South America Integrin Inhibitors Market Size by Country in 2025
Figure 54. South America Integrin Inhibitors Sales Market Share by Country (2021-2032)
Figure 55. South America Integrin Inhibitors Revenue Market Share by Country (2021-2032)
Figure 56. Brazil Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 57. Argentina Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 58. Chile Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 59. Middle East and Africa Integrin Inhibitors Market Size by Country in 2025
Figure 60. Middle East and Africa Integrin Inhibitors Sales Market Share by Country (2021-2032)
Figure 61. Middle East and Africa Integrin Inhibitors Revenue Market Share by Country (2021-2032)
Figure 62. Egypt Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 63. South Africa Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 64. Israel Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 65. Türkiye Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 66. GCC Countries Integrin Inhibitors Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 67. Global Integrin Inhibitors Sales Market Share by Type (2021-2032)
Figure 68. Global Integrin Inhibitors Revenue Market Share by Type (2021-2032)
Figure 69. Global Integrin Inhibitors Price (US$/Unit) by Type (2021-2032)
Figure 70. Global Integrin Inhibitors Sales Market Share by Application (2021-2032)
Figure 71. Global Integrin Inhibitors Revenue Market Share by Application (2021-2032)
Figure 72. Global Integrin Inhibitors Price (US$/Unit) by Application (2021-2032)
Figure 73. Integrin Inhibitors Value Chain
Figure 74. Integrin Inhibitors Production Mode & Process
Figure 75. Direct Comparison with Distribution Share
Figure 76. Distributors Profiles
Figure 77. Integrin Inhibitors Industry Opportunities and Challenges
Scope & coverage.
Types
- Antibodies
- Small Molecules
- Others
Applications
- Cardiovascular Disease
- Tumor
- Autoimmune Disease
- Other
Companies covered
- Grand Pharmaceutical
- Yangtze River Pharmaceutical
- Tianjin Chase Sun Pharma
- SJZ No.4 Pharmaceutical
- Lunan Pharma
- Kelun Pharma
- Huadong Medicin
- Bio-Thera Solutions
- Takeda
- Taj Pharmaceuticals
- Sandoz
- Polpharma Biologics
- Novartis
- Merck
- Medicure
- Johnson & Johnson
- GlaxoSmithKline
- Gland Pharma
- Eli Lilly
- Correvio
- Biogen
- Alvotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Integrin Inhibitors Market Size (2021-2032)
- 2.2.2 Global Integrin Inhibitors Sales (2021-2032)
- 2.2.3 Global Integrin Inhibitors Market Average Price (2021-2032)
- 2.3 Integrin Inhibitors by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Antibodies
- 2.3.3 Small Molecules
- 2.3.4 Others
- 2.4 Integrin Inhibitors by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cardiovascular Disease
- 2.4.3 Tumor
- 2.4.4 Autoimmune Disease
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Integrin Inhibitors Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Integrin Inhibitors Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Integrin Inhibitors Revenue of Manufacturers (2021-2026)
- 3.4 Global Integrin Inhibitors Average Price by Manufacturers (2021-2026)
- 3.5 Global Integrin Inhibitors Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Integrin Inhibitors, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Integrin Inhibitors, Product Type & Application
- 3.8 Global Manufacturers of Integrin Inhibitors, Established Date
- 3.9 Global Integrin Inhibitors Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Grand Pharmaceutical
- 4.1.1 Grand Pharmaceutical Company Information
- 4.1.2 Grand Pharmaceutical Business Overview
- 4.1.3 Grand Pharmaceutical Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Grand Pharmaceutical Integrin Inhibitors Product Portfolio
- 4.1.5 Grand Pharmaceutical Recent Developments
- 4.2 Yangtze River Pharmaceutical
- 4.2.1 Yangtze River Pharmaceutical Company Information
- 4.2.2 Yangtze River Pharmaceutical Business Overview
- 4.2.3 Yangtze River Pharmaceutical Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Yangtze River Pharmaceutical Integrin Inhibitors Product Portfolio
- 4.2.5 Yangtze River Pharmaceutical Recent Developments
- 4.3 Tianjin Chase Sun Pharma
- 4.3.1 Tianjin Chase Sun Pharma Company Information
- 4.3.2 Tianjin Chase Sun Pharma Business Overview
- 4.3.3 Tianjin Chase Sun Pharma Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Tianjin Chase Sun Pharma Integrin Inhibitors Product Portfolio
- 4.3.5 Tianjin Chase Sun Pharma Recent Developments
- 4.4 SJZ No.4 Pharmaceutical
- 4.4.1 SJZ No.4 Pharmaceutical Company Information
- 4.4.2 SJZ No.4 Pharmaceutical Business Overview
- 4.4.3 SJZ No.4 Pharmaceutical Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 SJZ No.4 Pharmaceutical Integrin Inhibitors Product Portfolio
- 4.4.5 SJZ No.4 Pharmaceutical Recent Developments
- 4.5 Lunan Pharma
- 4.5.1 Lunan Pharma Company Information
- 4.5.2 Lunan Pharma Business Overview
- 4.5.3 Lunan Pharma Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Lunan Pharma Integrin Inhibitors Product Portfolio
- 4.5.5 Lunan Pharma Recent Developments
- 4.6 Kelun Pharma
- 4.6.1 Kelun Pharma Company Information
- 4.6.2 Kelun Pharma Business Overview
- 4.6.3 Kelun Pharma Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Kelun Pharma Integrin Inhibitors Product Portfolio
- 4.6.5 Kelun Pharma Recent Developments
- 4.7 Huadong Medicin
- 4.7.1 Huadong Medicin Company Information
- 4.7.2 Huadong Medicin Business Overview
- 4.7.3 Huadong Medicin Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Huadong Medicin Integrin Inhibitors Product Portfolio
- 4.7.5 Huadong Medicin Recent Developments
- 4.8 Bio-Thera Solutions
- 4.8.1 Bio-Thera Solutions Company Information
- 4.8.2 Bio-Thera Solutions Business Overview
- 4.8.3 Bio-Thera Solutions Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Bio-Thera Solutions Integrin Inhibitors Product Portfolio
- 4.8.5 Bio-Thera Solutions Recent Developments
- 4.9 Takeda
- 4.9.1 Takeda Company Information
- 4.9.2 Takeda Business Overview
- 4.9.3 Takeda Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Takeda Integrin Inhibitors Product Portfolio
- 4.9.5 Takeda Recent Developments
- 4.10 Taj Pharmaceuticals
- 4.10.1 Taj Pharmaceuticals Company Information
- 4.10.2 Taj Pharmaceuticals Business Overview
- 4.10.3 Taj Pharmaceuticals Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Taj Pharmaceuticals Integrin Inhibitors Product Portfolio
- 4.10.5 Taj Pharmaceuticals Recent Developments
- 4.11 Sandoz
- 4.11.1 Sandoz Company Information
- 4.11.2 Sandoz Business Overview
- 4.11.3 Sandoz Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Sandoz Integrin Inhibitors Product Portfolio
- 4.11.5 Sandoz Recent Developments
- 4.12 Polpharma Biologics
- 4.12.1 Polpharma Biologics Company Information
- 4.12.2 Polpharma Biologics Business Overview
- 4.12.3 Polpharma Biologics Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Polpharma Biologics Integrin Inhibitors Product Portfolio
- 4.12.5 Polpharma Biologics Recent Developments
- 4.13 Novartis
- 4.13.1 Novartis Company Information
- 4.13.2 Novartis Business Overview
- 4.13.3 Novartis Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Novartis Integrin Inhibitors Product Portfolio
- 4.13.5 Novartis Recent Developments
- 4.14 Merck
- 4.14.1 Merck Company Information
- 4.14.2 Merck Business Overview
- 4.14.3 Merck Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Merck Integrin Inhibitors Product Portfolio
- 4.14.5 Merck Recent Developments
- 4.15 Medicure
- 4.15.1 Medicure Company Information
- 4.15.2 Medicure Business Overview
- 4.15.3 Medicure Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Medicure Integrin Inhibitors Product Portfolio
- 4.15.5 Medicure Recent Developments
- 4.16 Johnson & Johnson
- 4.16.1 Johnson & Johnson Company Information
- 4.16.2 Johnson & Johnson Business Overview
- 4.16.3 Johnson & Johnson Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Johnson & Johnson Integrin Inhibitors Product Portfolio
- 4.16.5 Johnson & Johnson Recent Developments
- 4.17 GlaxoSmithKline
- 4.17.1 GlaxoSmithKline Company Information
- 4.17.2 GlaxoSmithKline Business Overview
- 4.17.3 GlaxoSmithKline Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 GlaxoSmithKline Integrin Inhibitors Product Portfolio
- 4.17.5 GlaxoSmithKline Recent Developments
- 4.18 Gland Pharma
- 4.18.1 Gland Pharma Company Information
- 4.18.2 Gland Pharma Business Overview
- 4.18.3 Gland Pharma Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Gland Pharma Integrin Inhibitors Product Portfolio
- 4.18.5 Gland Pharma Recent Developments
- 4.19 Eli Lilly
- 4.19.1 Eli Lilly Company Information
- 4.19.2 Eli Lilly Business Overview
- 4.19.3 Eli Lilly Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Eli Lilly Integrin Inhibitors Product Portfolio
- 4.19.5 Eli Lilly Recent Developments
- 4.20 Correvio
- 4.20.1 Correvio Company Information
- 4.20.2 Correvio Business Overview
- 4.20.3 Correvio Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Correvio Integrin Inhibitors Product Portfolio
- 4.20.5 Correvio Recent Developments
- 4.21 Biogen
- 4.21.1 Biogen Company Information
- 4.21.2 Biogen Business Overview
- 4.21.3 Biogen Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.21.4 Biogen Integrin Inhibitors Product Portfolio
- 4.21.5 Biogen Recent Developments
- 4.22 Alvotech
- 4.22.1 Alvotech Company Information
- 4.22.2 Alvotech Business Overview
- 4.22.3 Alvotech Integrin Inhibitors Sales, Revenue and Gross Margin (2021-2026)
- 4.22.4 Alvotech Integrin Inhibitors Product Portfolio
- 4.22.5 Alvotech Recent Developments
5 Global Integrin Inhibitors Market Scenario by Region
- 5.1 Global Integrin Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Integrin Inhibitors Sales by Region: 2021-2032
- 5.2.1 Global Integrin Inhibitors Sales by Region: 2021-2026
- 5.2.2 Global Integrin Inhibitors Sales by Region: 2027-2032
- 5.3 Global Integrin Inhibitors Revenue by Region: 2021-2032
- 5.3.1 Global Integrin Inhibitors Revenue by Region: 2021-2026
- 5.3.2 Global Integrin Inhibitors Revenue by Region: 2027-2032
- 5.4 North America Integrin Inhibitors Market Facts & Figures by Country
- 5.4.1 North America Integrin Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Integrin Inhibitors Sales by Country (2021-2032)
- 5.4.3 North America Integrin Inhibitors Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Integrin Inhibitors Market Facts & Figures by Country
- 5.5.1 Europe Integrin Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Integrin Inhibitors Sales by Country (2021-2032)
- 5.5.3 Europe Integrin Inhibitors Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Integrin Inhibitors Market Facts & Figures by Country
- 5.6.1 Asia Pacific Integrin Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Integrin Inhibitors Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Integrin Inhibitors Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Integrin Inhibitors Market Facts & Figures by Country
- 5.7.1 South America Integrin Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Integrin Inhibitors Sales by Country (2021-2032)
- 5.7.3 South America Integrin Inhibitors Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Integrin Inhibitors Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Integrin Inhibitors Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Integrin Inhibitors Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Integrin Inhibitors Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Integrin Inhibitors Sales by Type (2021-2032)
- 6.1.1 Global Integrin Inhibitors Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Integrin Inhibitors Sales Market Share by Type (2021-2032)
- 6.2 Global Integrin Inhibitors Revenue by Type (2021-2032)
- 6.2.1 Global Integrin Inhibitors Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Integrin Inhibitors Revenue Market Share by Type (2021-2032)
- 6.3 Global Integrin Inhibitors Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Integrin Inhibitors Sales by Application (2021-2032)
- 7.1.1 Global Integrin Inhibitors Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Integrin Inhibitors Sales Market Share by Application (2021-2032)
- 7.2 Global Integrin Inhibitors Revenue by Application (2021-2032)
- 7.2.1 Global Integrin Inhibitors Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Integrin Inhibitors Revenue Market Share by Application (2021-2032)
- 7.3 Global Integrin Inhibitors Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Integrin Inhibitors Value Chain Analysis
- 8.1.1 Integrin Inhibitors Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Integrin Inhibitors Production Mode & Process
- 8.2 Integrin Inhibitors Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Integrin Inhibitors Distributors
- 8.2.3 Integrin Inhibitors Customers
9 Global Integrin Inhibitors Analyzing Market Dynamics
- 9.1 Integrin Inhibitors Industry Trends
- 9.2 Integrin Inhibitors Industry Drivers
- 9.3 Integrin Inhibitors Industry Opportunities and Challenges
- 9.4 Integrin Inhibitors Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst